Kendrick Tony, El-Gohary Magdy, Stuart Beth, Gilbody Simon, Churchill Rachel, Aiken Laura, Bhattacharya Abhishek, Gimson Amy, Brütt Anna L, de Jong Kim, Moore Michael
Primary Care and Population Sciences, Faculty of Medicine, Aldermoor Health Centre, University of Southampton, Aldermoor Close, Southampton, UK, SO16 5ST.
Cochrane Database Syst Rev. 2016 Jul 13;7(7):CD011119. doi: 10.1002/14651858.CD011119.pub2.
Routine outcome monitoring of common mental health disorders (CMHDs), using patient reported outcome measures (PROMs), has been promoted across primary care, psychological therapy and multidisciplinary mental health care settings, but is likely to be costly, given the high prevalence of CMHDs. There has been no systematic review of the use of PROMs in routine outcome monitoring of CMHDs across these three settings.
To assess the effects of routine measurement and feedback of the results of PROMs during the management of CMHDs in 1) improving the outcome of CMHDs; and 2) in changing the management of CMHDs.
We searched the Cochrane Depression Anxiety and Neurosis group specialised controlled trials register (CCDANCTR-Studies and CCDANCTR-References), the Oxford University PROMS Bibliography (2002-5), Ovid PsycINFO, Web of Science, The Cochrane Library, and International trial registries, initially to 30 May 2014, and updated to 18 May 2015.
We selected cluster and individually randomised controlled trials (RCTs) including participants with CMHDs aged 18 years and over, in which the results of PROMs were fed back to treating clinicians, or both clinicians and patients. We excluded RCTs in child and adolescent treatment settings, and those in which more than 10% of participants had diagnoses of eating disorders, psychoses, substance use disorders, learning disorders or dementia.
At least two authors independently identified eligible trials, assessed trial quality, and extracted data. We conducted meta-analysis across studies, pooling outcome measures which were sufficiently similar to each other to justify pooling.
We included 17 studies involving 8787 participants: nine in multidisciplinary mental health care, six in psychological therapy settings, and two in primary care. Pooling of outcome data to provide a summary estimate of effect across studies was possible only for those studies using the compound Outcome Questionnaire (OQ-45) or Outcome Rating System (ORS) PROMs, which were all conducted in multidisciplinary mental health care or psychological therapy settings, because both primary care studies identified used single symptom outcome measures, which were not directly comparable to the OQ-45 or ORS.Meta-analysis of 12 studies including 3696 participants using these PROMs found no evidence of a difference in outcome in terms of symptoms, between feedback and no-feedback groups (standardised mean difference (SMD) -0.07, 95% confidence interval (CI) -0.16 to 0.01; P value = 0.10). The evidence for this comparison was graded as low quality however, as all included studies were considered at high risk of bias, in most cases due to inadequate blinding of assessors and significant attrition at follow-up.Quality of life was reported in only two studies, social functioning in one, and costs in none. Information on adverse events (thoughts of self-harm or suicide) was collected in one study, but differences between arms were not reported.It was not possible to pool data on changes in drug treatment or referrals as only two studies reported these. Meta-analysis of seven studies including 2608 participants found no evidence of a difference in management of CMHDs between feedback and no-feedback groups, in terms of the number of treatment sessions received (mean difference (MD) -0.02 sessions, 95% CI -0.42 to 0.39; P value = 0.93). However, the evidence for this comparison was also graded as low quality.
AUTHORS' CONCLUSIONS: We found insufficient evidence to support the use of routine outcome monitoring using PROMs in the treatment of CMHDs, in terms of improving patient outcomes or in improving management. The findings are subject to considerable uncertainty however, due to the high risk of bias in the large majority of trials meeting the inclusion criteria, which means further research is very likely to have an important impact on the estimate of effect and is likely to change the estimate. More research of better quality is therefore required, particularly in primary care where most CMHDs are treated.Future research should address issues of blinding of assessors and attrition, and measure a range of relevant symptom outcomes, as well as possible harmful effects of monitoring, health-related quality of life, social functioning, and costs. Studies should include people treated with drugs as well as psychological therapies, and should follow them up for longer than six months.
使用患者报告结局测量工具(PROMs)对常见精神障碍(CMHDs)进行常规结局监测,已在初级保健、心理治疗和多学科心理健康护理环境中得到推广,但鉴于CMHDs的高患病率,这可能成本高昂。目前尚无对这三种环境中使用PROMs进行CMHDs常规结局监测的系统评价。
评估在CMHDs管理过程中对PROMs结果进行常规测量和反馈的效果,包括:1)改善CMHDs的结局;2)改变CMHDs的管理方式。
我们检索了Cochrane抑郁、焦虑和神经症小组专门的对照试验注册库(CCDANCTR - 研究和CCDANCTR - 参考文献)、牛津大学PROMs文献目录(2002 - 2005年)、Ovid PsycINFO、科学网、Cochrane图书馆以及国际试验注册库,最初检索至2014年5月30日,并更新至2015年5月18日。
我们选择了整群随机对照试验和个体随机对照试验(RCTs),纳入年龄在18岁及以上的CMHDs患者,其中PROMs的结果反馈给治疗临床医生,或同时反馈给临床医生和患者。我们排除了儿童和青少年治疗环境中的RCTs,以及超过10%的参与者被诊断患有饮食失调、精神病、物质使用障碍、学习障碍或痴呆症的试验。
至少两名作者独立识别符合条件的试验,评估试验质量,并提取数据。我们对各项研究进行荟萃分析,合并彼此足够相似以证明可合并的结局测量指标。
我们纳入了17项研究,涉及8787名参与者:9项在多学科心理健康护理环境中,6项在心理治疗环境中,2项在初级保健环境中。仅对于那些使用复合结局问卷(OQ - 45)或结局评定系统(ORS)PROMs的研究,才有可能合并结局数据以提供各项研究效应汇总估计值,这些研究均在多学科心理健康护理或心理治疗环境中进行,因为两项初级保健研究均采用单一症状结局测量指标,与OQ - 45或ORS不具有直接可比性。对12项包括3696名使用这些PROMs的参与者的研究进行荟萃分析发现,在症状方面,反馈组和无反馈组之间没有证据表明结局存在差异(标准化均数差(SMD) - 0.07,95%置信区间(CI) - 0.16至0.01;P值 = 0.10)。然而,该比较的证据质量被评为低质量,因为所有纳入研究在大多数情况下因评估者未充分设盲和随访时显著失访而被认为存在高偏倚风险。仅两项研究报告了生活质量,一项报告了社会功能,没有研究报告成本。一项研究收集了不良事件(自我伤害或自杀念头)的信息,但未报告各分组之间的差异。由于仅有两项研究报告了药物治疗或转诊的变化,因此无法合并相关数据。对7项包括2608名参与者的研究进行荟萃分析发现,在接受治疗的疗程数方面,反馈组和无反馈组之间没有证据表明在CMHDs管理上存在差异(均数差(MD) - 0.02个疗程,95% CI - 0.42至0.39;P值 = 0.93)。然而,该比较的证据质量也被评为低质量。
我们发现没有足够的证据支持在CMHDs治疗中使用PROMs进行常规结局监测以改善患者结局或改善管理。然而,由于大多数符合纳入标准的试验存在高偏倚风险,这些发现存在相当大的不确定性,这意味着进一步的研究很可能对效应估计产生重要影响,并可能改变估计值。因此,需要更多质量更高的研究,特别是在大多数CMHDs患者接受治疗的初级保健环境中。未来的研究应解决评估者设盲和失访问题,并测量一系列相关症状结局,以及监测可能产生的有害影响、健康相关生活质量、社会功能和成本。研究应包括接受药物治疗和心理治疗的人群,并应进行超过六个月的随访。